1 min read
Co-Diagnostics Sets 1-for-25 Reverse Stock Split for Nov. 24
The Nasdaq-listed company announced Thursday that the split of its issued and outstanding common stock takes effect Tuesday. Every 25 shares will be combined into one.

Co-Diagnostics, Inc. (Nasdaq: CODX) announced Thursday that it will carry out a 1-for-25 reverse split of its issued and outstanding common stock, effective Tuesday, Nov. 24.
Under the 1-for-25 ratio, every 25 shares a holder owns will be combined into one share. A reverse split reduces the number of shares outstanding and, all else equal, raises the per-share price.
The split applies to the company's issued and outstanding common stock. Co-Diagnostics made the announcement Nov. 19.
The split is scheduled to take effect Nov. 24.